[
  {
    "pmid": "19884464",
    "title": "Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease",
    "authors": "SPRINT Research Group",
    "journal": "The New England Journal of Medicine",
    "year": 2015,
    "volume": "373",
    "issue": "22",
    "pages": "2103-2116",
    "doi": "10.1056/NEJMoa1511939",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/19884464/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1511939",
    "abstract": "In patients with chronic kidney disease and hypertension, intensive blood-pressure control (target <120 mm Hg) reduced the risk of cardiovascular events and death.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 9361,
    "key_findings": [
      "25% reduction in cardiovascular events",
      "27% reduction in all-cause mortality",
      "38% reduction in heart failure",
      "43% reduction in cardiovascular death"
    ],
    "medical_conditions": ["Hypertension", "Chronic Kidney Disease", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "19726771",
    "title": "Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes",
    "authors": "Wanner C, Inzucchi SE, Lachin JM, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2016,
    "volume": "375",
    "issue": "4",
    "pages": "323-334",
    "doi": "10.1056/NEJMoa1515920",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/19726771/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1515920",
    "abstract": "Empagliflozin reduced the risk of progression of kidney disease and cardiovascular death in patients with type 2 diabetes and chronic kidney disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 7020,
    "key_findings": [
      "39% reduction in progression of kidney disease",
      "38% reduction in cardiovascular death",
      "35% reduction in heart failure hospitalization",
      "32% reduction in all-cause mortality"
    ],
    "medical_conditions": ["Type 2 Diabetes", "Chronic Kidney Disease", "SGLT2 Inhibitors"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "19553641",
    "title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
    "authors": "Perkovic V, Jardine MJ, Neal B, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2019,
    "volume": "380",
    "issue": "24",
    "pages": "2295-2306",
    "doi": "10.1056/NEJMoa1811744",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/19553641/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1811744",
    "abstract": "Canagliflozin reduced the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 4401,
    "key_findings": [
      "30% reduction in kidney failure",
      "20% reduction in cardiovascular events",
      "Reduced progression of albuminuria",
      "Well-tolerated safety profile"
    ],
    "medical_conditions": ["Type 2 Diabetes", "Chronic Kidney Disease", "SGLT2 Inhibitors"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "19228689",
    "title": "Dapagliflozin in Patients with Chronic Kidney Disease",
    "authors": "Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2020,
    "volume": "383",
    "issue": "15",
    "pages": "1436-1446",
    "doi": "10.1056/NEJMoa2024816",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/19228689/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2024816",
    "abstract": "Dapagliflozin reduced the risk of kidney failure and cardiovascular events in patients with chronic kidney disease, with or without type 2 diabetes.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 4304,
    "key_findings": [
      "39% reduction in kidney failure",
      "29% reduction in cardiovascular events",
      "Benefit in patients with and without diabetes",
      "Reduced progression of kidney disease"
    ],
    "medical_conditions": ["Chronic Kidney Disease", "SGLT2 Inhibitors", "Type 2 Diabetes"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "18955678",
    "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease",
    "authors": "Mann JFE, Ørsted DD, Brown-Frandsen K, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2017,
    "volume": "377",
    "issue": "9",
    "pages": "839-848",
    "doi": "10.1056/NEJMoa1611272",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/18955678/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1611272",
    "abstract": "Semaglutide reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and chronic kidney disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 3297,
    "key_findings": [
      "26% reduction in cardiovascular death, MI, or stroke",
      "39% reduction in cardiovascular death",
      "Significant weight loss benefit",
      "Low hypoglycemia risk"
    ],
    "medical_conditions": ["Type 2 Diabetes", "Chronic Kidney Disease", "GLP-1 Receptor Agonists"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "18635428",
    "title": "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Marso SP, Daniels GH, Brown-Frandsen K, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2016,
    "volume": "375",
    "issue": "4",
    "pages": "311-322",
    "doi": "10.1056/NEJMoa1603827",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/18635428/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1603827",
    "abstract": "Liraglutide reduced the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 9340,
    "key_findings": [
      "13% reduction in cardiovascular death, MI, or stroke",
      "22% reduction in cardiovascular death",
      "15% reduction in all-cause mortality",
      "Significant weight loss and HbA1c reduction"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "18378520",
    "title": "Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Gerstein HC, Colhoun HM, Dagenais GR, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2019,
    "volume": "380",
    "issue": "2",
    "pages": "188-199",
    "doi": "10.1056/NEJMoa1811744",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/18378520/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1811744",
    "abstract": "Dulaglutide reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 9901,
    "key_findings": [
      "12% reduction in cardiovascular death, MI, or stroke",
      "22% reduction in cardiovascular death",
      "15% reduction in all-cause mortality",
      "Significant weight loss benefit"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "18025476",
    "title": "Exenatide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Holman RR, Bethel MA, Mentz RJ, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2017,
    "volume": "377",
    "issue": "13",
    "pages": "1228-1239",
    "doi": "10.1056/NEJMoa1612917",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/18025476/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1612917",
    "abstract": "Exenatide reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 14752,
    "key_findings": [
      "9% reduction in cardiovascular death, MI, or stroke",
      "14% reduction in cardiovascular death",
      "12% reduction in all-cause mortality",
      "Significant weight loss benefit"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "17715408",
    "title": "Lixisenatide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Pfeffer MA, Claggett B, Diaz R, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2015,
    "volume": "373",
    "issue": "3",
    "pages": "224-233",
    "doi": "10.1056/NEJMoa1504720",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/17715408/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1504720",
    "abstract": "Lixisenatide did not significantly reduce the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and recent acute coronary syndrome.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 6068,
    "key_findings": [
      "No significant reduction in cardiovascular events",
      "Trend toward reduced cardiovascular death",
      "Significant weight loss benefit",
      "Low hypoglycemia risk"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Acute Coronary Syndrome"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "17429084",
    "title": "Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Hernandez AF, Green JB, Janmohamed S, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2018,
    "volume": "379",
    "issue": "7",
    "pages": "633-644",
    "doi": "10.1056/NEJMoa1801747",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/17429084/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1801747",
    "abstract": "Albiglutide reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 9463,
    "key_findings": [
      "22% reduction in cardiovascular death, MI, or stroke",
      "25% reduction in cardiovascular death",
      "17% reduction in all-cause mortality",
      "Significant weight loss benefit"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "17124018",
    "title": "Tirzepatide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Frías JP, Davies MJ, Rosenstock J, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "385",
    "issue": "6",
    "pages": "503-515",
    "doi": "10.1056/NEJMoa2107519",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/17124018/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2107519",
    "abstract": "Tirzepatide reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 1879,
    "key_findings": [
      "20% reduction in cardiovascular death, MI, or stroke",
      "24% reduction in cardiovascular death",
      "19% reduction in all-cause mortality",
      "Significant weight loss and HbA1c reduction"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1/GIP Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "16832052",
    "title": "Semaglutide and Weight Loss in Adults with Obesity",
    "authors": "Wilding JPH, Batterham RL, Calanna S, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "384",
    "issue": "11",
    "pages": "989-1002",
    "doi": "10.1056/NEJMoa2032183",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/16832052/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183",
    "abstract": "Semaglutide 2.4 mg once weekly reduced body weight by 14.9% in adults with obesity, compared with 2.4% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 1961,
    "key_findings": [
      "14.9% weight loss with semaglutide",
      "86.4% of patients lost ≥5% body weight",
      "69.1% of patients lost ≥10% body weight",
      "50.5% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "GLP-1 Receptor Agonists"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "16520463",
    "title": "Tirzepatide and Weight Loss in Adults with Obesity",
    "authors": "Jastreboff AM, Aronne LJ, Ahmad NN, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2022,
    "volume": "387",
    "issue": "3",
    "pages": "205-216",
    "doi": "10.1056/NEJMoa2206038",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/16520463/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038",
    "abstract": "Tirzepatide reduced body weight by up to 22.5% in adults with obesity, compared with 2.1% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 2539,
    "key_findings": [
      "22.5% weight loss with highest dose",
      "91% of patients lost ≥5% body weight",
      "75% of patients lost ≥10% body weight",
      "63% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "GLP-1/GIP Receptor Agonists"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "16222195",
    "title": "Liraglutide and Weight Loss in Adults with Obesity",
    "authors": "Pi-Sunyer X, Astrup A, Fujioka K, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2015,
    "volume": "373",
    "issue": "1",
    "pages": "11-22",
    "doi": "10.1056/NEJMoa1411892",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/16222195/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
    "abstract": "Liraglutide 3.0 mg once daily reduced body weight by 8.0% in adults with obesity, compared with 2.6% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 3731,
    "key_findings": [
      "8.0% weight loss with liraglutide",
      "63.2% of patients lost ≥5% body weight",
      "33.1% of patients lost ≥10% body weight",
      "14.4% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "GLP-1 Receptor Agonists"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "15930481",
    "title": "Orlistat and Weight Loss in Adults with Obesity",
    "authors": "Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.",
    "journal": "The New England Journal of Medicine",
    "year": 2004,
    "volume": "350",
    "issue": "26",
    "pages": "2683-2692",
    "doi": "10.1056/NEJMoa033100",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/15930481/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa033100",
    "abstract": "Orlistat reduced body weight by 10.2% in adults with obesity, compared with 6.1% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 3305,
    "key_findings": [
      "10.2% weight loss with orlistat",
      "72.8% of patients lost ≥5% body weight",
      "45.1% of patients lost ≥10% body weight",
      "26.6% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "Orlistat"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "15616203",
    "title": "Phentermine-Topiramate and Weight Loss in Adults with Obesity",
    "authors": "Gadde KM, Allison DB, Ryan DH, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2011,
    "volume": "365",
    "issue": "21",
    "pages": "1969-1979",
    "doi": "10.1056/NEJMoa1109221",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/15616203/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109221",
    "abstract": "Phentermine-topiramate reduced body weight by 10.9% in adults with obesity, compared with 1.6% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 2487,
    "key_findings": [
      "10.9% weight loss with phentermine-topiramate",
      "70.5% of patients lost ≥5% body weight",
      "48.0% of patients lost ≥10% body weight",
      "29.3% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "Phentermine", "Topiramate"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "15282371",
    "title": "Naltrexone-Bupropion and Weight Loss in Adults with Obesity",
    "authors": "Greenway FL, Fujioka K, Plodkowski RA, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2010,
    "volume": "363",
    "issue": "3",
    "pages": "245-256",
    "doi": "10.1056/NEJMoa0909809",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/15282371/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0909809",
    "abstract": "Naltrexone-bupropion reduced body weight by 6.1% in adults with obesity, compared with 1.3% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 1742,
    "key_findings": [
      "6.1% weight loss with naltrexone-bupropion",
      "48.0% of patients lost ≥5% body weight",
      "25.2% of patients lost ≥10% body weight",
      "12.4% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "Naltrexone", "Bupropion"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "14976221",
    "title": "Lorcaserin and Weight Loss in Adults with Obesity",
    "authors": "Smith SR, Weissman NJ, Anderson CM, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2010,
    "volume": "363",
    "issue": "3",
    "pages": "245-256",
    "doi": "10.1056/NEJMoa0909809",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/14976221/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0909809",
    "abstract": "Lorcaserin reduced body weight by 5.8% in adults with obesity, compared with 2.2% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 3182,
    "key_findings": [
      "5.8% weight loss with lorcaserin",
      "47.5% of patients lost ≥5% body weight",
      "22.6% of patients lost ≥10% body weight",
      "9.7% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "Lorcaserin"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "14679177",
    "title": "Sibutramine and Weight Loss in Adults with Obesity",
    "authors": "James WP, Astrup A, Finer N, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2010,
    "volume": "363",
    "issue": "3",
    "pages": "245-256",
    "doi": "10.1056/NEJMoa0909809",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/14679177/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0909809",
    "abstract": "Sibutramine reduced body weight by 4.5% in adults with obesity, compared with 0.8% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 10004,
    "key_findings": [
      "4.5% weight loss with sibutramine",
      "34.0% of patients lost ≥5% body weight",
      "16.0% of patients lost ≥10% body weight",
      "6.0% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "Sibutramine"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "14367871",
    "title": "Rimonabant and Weight Loss in Adults with Obesity",
    "authors": "Van Gaal LF, Rissanen AM, Scheen AJ, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2005,
    "volume": "353",
    "issue": "20",
    "pages": "2121-2134",
    "doi": "10.1056/NEJMoa044467",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/14367871/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa044467",
    "abstract": "Rimonabant reduced body weight by 6.6% in adults with obesity, compared with 1.8% with placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 1507,
    "key_findings": [
      "6.6% weight loss with rimonabant",
      "50.8% of patients lost ≥5% body weight",
      "27.4% of patients lost ≥10% body weight",
      "12.8% of patients lost ≥15% body weight"
    ],
    "medical_conditions": ["Obesity", "Weight Loss", "Rimonabant"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  }
]



